26th March 2018

(1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sirs,

Please find enclosed Press Release dated 26th March 2018.

Kindly acknowledge the receipt.

Thank you,

Yours faithfully,
For Cipla Limited

[Signature]

Ashish Chauhan
Senior Manager – Corporate Secretarial

Encl: as above
Press Release

Cipla Launches Authorized Generic of Aloxi®
(Palonosetron HCl Injection 0.25 mg/5 ml)

Mumbai, India, March 26, 2018: Cipla USA, Inc. (“Cipla”) announces the launch of an authorized generic version of Aloxi® in the United States under applicable agreements with Helsinn Healthcare SA, in response to the at-risk launch by Teva.

Helsinn Healthcare SA currently manufactures and markets Aloxi® in the United States through its licensee Eisai Inc. and its affiliate Helsinn Therapeutics (US) Inc. Aloxi® containing palonosetron hydrochloride injections (Eq. 0.25 mg base/5 ml) is indicated for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy and for prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.

According to IMS Health, Aloxi® brand had U.S. sales of approximately $460M for the 12-month period ending November 2017.

Cipla’s Authorized Generic of Aloxi® is available for shipping immediately.

About Cipla:

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For over 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 80 countries. Our portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001. Cipla’s research and development focuses on developing innovative products and drug delivery systems.

Media Contacts for Cipla Limited:

Corporate Communications
Pallavi Golar
E Mail: pallavi.golar@cipla.com

Investor Relations
Naveen Bansal
E-Mail: Investor.Relations@cipla.com